Olympiad Research LP Invests $448,000 in Illumina, Inc. (NASDAQ:ILMN)

Olympiad Research LP bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 3,355 shares of the life sciences company’s stock, valued at approximately $448,000.

A number of other institutional investors also recently modified their holdings of the stock. Empowered Funds LLC lifted its position in shares of Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock valued at $516,000 after acquiring an additional 66 shares during the period. Bank of Stockton lifted its position in shares of Illumina by 3.8% during the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after acquiring an additional 80 shares during the period. Caprock Group LLC lifted its position in shares of Illumina by 3.0% during the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock valued at $376,000 after acquiring an additional 83 shares during the period. Integrated Advisors Network LLC increased its stake in Illumina by 2.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock valued at $585,000 after purchasing an additional 90 shares in the last quarter. Finally, Stephens Inc. AR increased its stake in Illumina by 1.4% during the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after purchasing an additional 90 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on ILMN. JPMorgan Chase & Co. boosted their price target on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Piper Sandler boosted their price target on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Royal Bank of Canada decreased their price target on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Barclays lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and decreased their price target for the company from $130.00 to $100.00 in a research note on Monday, February 10th. Finally, Canaccord Genuity Group decreased their price target on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $159.45.

Illumina Price Performance

ILMN opened at $94.20 on Friday. The firm has a market cap of $14.92 billion, a P/E ratio of -12.27, a PEG ratio of 1.60 and a beta of 1.10. The firm has a 50-day moving average of $127.98 and a 200 day moving average of $134.13. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a fifty-two week low of $93.50 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.